CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

CRISPR Therapeutics (CRSP) is presented as the more favorable investment over Intellia Therapeutics (NTLA), primarily due to CRSP's first-to-market CRISPR/Cas9 therapy, Casgevy, approved in the US and EU for SCD and TDT. Despite slow initial commercial uptake for Casgevy, CRSP maintains a strong $1.9 billion cash balance and a diversified pipeline with promising early-stage in vivo programs, contributing to its 19% year-to-date stock gain. In contrast, NTLA lacks an approved product, recently suffered a significant clinical setback with its late-stage nex-z candidate due to liver safety concerns, and holds a smaller $707 million cash reserve, reflecting its 18% year-to-date stock decline.

Analysis

CRISPR Therapeutics (CRSP) has established a significant lead over Intellia Therapeutics (NTLA) by securing the world's first approval for a CRISPR/Cas9 therapy, Casgevy, for sickle cell disease and beta thalassemia. Despite a slow commercial uptake, with approximately 90 patients having completed cell collection as of May 1, the partnership with Vertex Pharmaceuticals and the activation of over 65 treatment centers provide a foundation for future growth. CRSP's strategic advantage is further solidified by a diversified pipeline that includes not only ex vivo therapies but also promising early-stage in vivo candidates like CTX310, which showed dose-dependent LDL and triglyceride reductions. This is supported by a strong balance sheet with $1.9 billion in cash and a 19% year-to-date stock price increase. In contrast, Intellia faces considerable headwinds. The company has no marketed products and recently suffered a major clinical setback with its late-stage candidate nex-z, which caused a grade 4 liver adverse event, raising significant safety concerns. This event overshadows the progress of its other late-stage candidate, lonvo-z, and has contributed to a strategic reorganization involving a 27% workforce reduction. NTLA's weaker financial position, with $707 million in cash, and an 18% year-to-date stock decline reflect the heightened clinical and financial risk. While CRSP's 2025 loss estimates are widening, NTLA's are narrowing, but this is likely a function of restructuring rather than fundamental strength. Consequently, CRSP's higher price-to-book ratio of 2.21 versus NTLA's 1.27 appears justified by its de-risked commercial status and broader pipeline optionality.

Key Decisions for Investors

• Investors should monitor the commercial ramp-up of CRSP's Casgevy, as accelerating patient starts is critical to justifying its current valuation and funding its diversified, yet early-stage, pipeline.
• The primary risk for NTLA is the resolution of the liver safety signal for its lead candidate nex-z; the stock remains a high-risk, event-driven holding until there is definitive clarity on the therapy's safety profile.
• Despite a higher valuation, CRSP presents a more favorable risk/reward profile due to its approved product, strong cash position, and diversified pipeline, making it a comparatively safer investment within the volatile gene-editing space.
• Consider the divergent performance and fundamentals as a basis for a pairs trade, favoring a long position in CRSP against a short position in NTLA to capture the widening gap in commercial execution and clinical risk.